Literature DB >> 8655288

Methylxanthines with adenosine alter TNF alpha-primed PMN activation.

G W Sullivan1, L S Luong, H T Carper, R C Barnes, G L Mandell.   

Abstract

Methylxanthines are best known as phosphodiesterase inhibitors that cause a rise in intracellular cAMP. One would expect the two methylxanthines, caffeine and pentoxifylline, to have similar actions on neutrophils (PMN). However, caffeine stimulated and pentoxifylline inhibited PMN oxidative activity. Micromolar concentrations of pentoxifylline decreased native and recombinant tumor necrosis factor-alpha (TNF alpha)-primed formyl met-leu-phe (fMLP)-stimulated PMN chemiluminescence, superoxide production and myeloperoxidase (MPO) release. In contrast, equal concentrations of caffeine increased chemiluminescence and MPO release with no effect on superoxide production. These activities of the methylxanthines were only observed in the presence of physiological concentrations of adenosine, and were abolished by the treatment of the PMN with adenosine deaminase. The activities of adenosine, pentoxifylline and caffeine on PMN activity could not be readily explained by changes in PMN [cAMP]. Thus for TNF alpha-primed PMN, pentoxifylline decreases PMN activity by enhancing the effect of adenosine on degranulation and superoxide production; whereas caffeine increases PMN activity by counteracting the effect of adenosine on degranulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8655288     DOI: 10.1016/0162-3109(95)00030-0

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  2 in total

Review 1.  Caffeine and cardiovascular diseases: critical review of current research.

Authors:  Anthony Zulli; Renee M Smith; Peter Kubatka; Jan Novak; Yoshio Uehara; Hayley Loftus; Tawar Qaradakhi; Miroslav Pohanka; Nazarii Kobyliak; Angela Zagatina; Jan Klimas; Alan Hayes; Giampiero La Rocca; Miroslav Soucek; Peter Kruzliak
Journal:  Eur J Nutr       Date:  2016-03-01       Impact factor: 5.614

2.  Adenosine in inflammatory joint diseases.

Authors:  E S L Chan; P Fernandez; B N Cronstein
Journal:  Purinergic Signal       Date:  2007-01-03       Impact factor: 3.765

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.